Erectile Dysfunction Risk Among Patients With Diabetes Mellitus Using Sodium-Glucose Cotransporter 2 Inhibitors.

IF 2.6 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Cardiovascular Pharmacology Pub Date : 2024-11-01 DOI:10.1097/FJC.0000000000001624

Wei-Syun Hu, Cheng-Li Lin

引用次数: 0

Abstract

Abstract: The aim of this study was to explore the incidence of new-onset erectile dysfunction (ED) in diabetes mellitus (DM) patients with sodium-glucose cotransporter 2 inhibitors (SGLT2I) use compared with a control group of non-SGLT2I use by propensity score matching approach. Cox proportional hazards regression models were used to examine the effect of SGLT2I and risk factors on the risk of developing ED, presented as a hazard ratio with a 95% confidence interval. One lakhs fifty nine thousand seven hundred seventy three patients with DM using SGLT2I and 159,773 propensity score matching patients with DM who had never used SGLT2I were included. SGLT2I users had a higher risk of ED than the non-SGLT2I users (adjusted hazard ratio = 1.55, 95% confidence interval = 1.40-1.72). The likelihood of developing ED was higher in patients with SGLT2I use was found.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用钠-葡萄糖共转运体 2 抑制剂的糖尿病患者出现勃起功能障碍的风险。

通过倾向匹配（PS）方法，探讨使用钠-葡萄糖共转运体2抑制剂（SGLT2I）的糖尿病（DM）患者与未使用SGLT2I的对照组相比，新发勃起功能障碍（ED）的发生率。采用 Cox 比例危险度回归模型来检验 SGLT2I 和风险因素对罹患 ED 风险的影响，结果显示为危险比 (HR) 和 95% 置信区间 (CI)。共纳入了 159773 名使用 SGLT2I 的 DM 患者和 159773 名从未使用过 SGLT2I 的 PS 匹配 DM 患者。与未使用 SGLT2I 的患者相比，使用 SGLT2I 的患者发生 ED 的风险更高（调整后 HR = 1.55，95% CI = 1.40-1.72）。研究发现，使用 SGLT2I 的患者发生 ED 的可能性更高。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Cardiovascular Pharmacology 医学-心血管系统

CiteScore

5.10

自引率

3.30%

发文量

367

审稿时长

1 months

期刊介绍： Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias. Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.